新聞與行事曆

Skip Navigation Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Key Points The U.S. struck a deal with Venezuela to get majority control of more than 65 billion barrels of oil reserves, according to President Donald Trump. Trump said the deal comes "at no cost to" U.S. taxpayers. In this article @CL.1 @LCO27F Follow your favorite stocks CREATE FREE ACCOUNT US President Donald Trump speaks in the Rose Garden of the White House in Washington, DC, on Aug. 24, 2026. Jim Watson | AFP | Getty Images The U.S. struck a deal with Venezuela…

What Do Moderna (MRNA) FDA Vaccine Approvals Mean For Its Respiratory Push? Bailey Pemberton Sun, August 30, 2026 at 1:09 PM GMT+10 3 min read MRNA Moderna (NasdaqGS:MRNA) received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant. The FDA also cleared mFlusiva, Moderna's first mRNA based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA authorized mRNA flu shot for older adults. To see how other companies in this space are using similar technology, ex…

Skip Navigation Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Key Points OpenAI plans to wind down its contract supplying models to Cursor, with a proposed Nov. 12 cutoff. OpenAI says it cannot be confident SpaceX will comply with its terms, citing past disputes with Elon Musk’s companies. CEO Michael Truell says OpenAI models account for about 5% of Cursor user traffic and that the companies are discussing the decision. In this article SPCX Follow your favorite stocks CREATE FREE ACCOUNT A combination photo shows CEO of OpenAI Sam Altman…

By Michael Erman and Julie Steenhuysen Aug 28 (Reuters) – Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant celebrating a friend’s birthday late on August 13 when he got the call. An mRNA cancer vaccine the company had been developing with Merck had hit its mark — the first success of a therapeutic cancer vaccine in late-stage testing after more than 100 years of failed attempts. Cancer experts hailed it as the beginning of an era of custom-made vaccines that train the immune system to fight an individual patient’s cancer. In a ​trial of more than 1,000 patients with localized mela…